B. Riley Comments on Harrow’s Q1 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – Investment analysts at B. Riley dropped their Q1 2025 earnings per share estimates for shares of Harrow in a research note issued to investors on Monday, March 31st. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($0.01) per share for the quarter, down from their previous forecast of $0.15. B. Riley currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow’s FY2025 earnings at $0.78 EPS, FY2026 earnings at $2.67 EPS and FY2027 earnings at $4.79 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Harrow in a research report on Monday.

Harrow Trading Up 4.3 %

Shares of HROW opened at $26.05 on Thursday. Harrow has a 1-year low of $9.86 and a 1-year high of $59.23. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The firm has a 50 day simple moving average of $28.36 and a 200-day simple moving average of $37.63. The stock has a market cap of $927.77 million, a price-to-earnings ratio of -27.71 and a beta of 0.69.

Harrow (NASDAQ:HROW) last announced its earnings results on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. The company had revenue of $66.83 million during the quarter, compared to analysts’ expectations of $66.01 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%.

Institutional Investors Weigh In On Harrow

A number of institutional investors have recently bought and sold shares of HROW. Braidwell LP boosted its holdings in shares of Harrow by 106.3% in the 4th quarter. Braidwell LP now owns 907,039 shares of the company’s stock valued at $30,431,000 after purchasing an additional 467,401 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Harrow by 443.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after buying an additional 194,480 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after acquiring an additional 166,602 shares during the last quarter. Two Sigma Investments LP grew its position in Harrow by 483.2% during the fourth quarter. Two Sigma Investments LP now owns 150,355 shares of the company’s stock valued at $5,044,000 after acquiring an additional 124,574 shares during the period. Finally, Neuberger Berman Group LLC increased its stake in Harrow by 128.0% during the fourth quarter. Neuberger Berman Group LLC now owns 200,529 shares of the company’s stock worth $6,728,000 after acquiring an additional 112,588 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.